Galapagos Signs Supply Agreement with Johnson & Johnson Pharmaceutical Research & Development
News Mar 08, 2007
Galapagos NV has announced that its service division, BioFocus DPI, has entered into an agreement to supply small molecule compounds for drug discovery to the Johnson & Johnson Pharmaceutical Research & Development Division of Janssen Pharmaceutica NV.
Under the terms of the two-year agreement, BioFocus DPI will provide access to compounds from its SoftFocus small molecule libraries and will also generate customer specific compound library sets for use in J&JPRD's drug discovery programs. Financial terms were not disclosed.
"This supply agreement is a natural expansion of our drug discovery relationship with J&JPRD. It will give J&JPRD access to highly targeted drug building blocks for their drug discovery programs," said Onno van de Stolpe, Chief Executive Officer of Galapagos.